Indeed, an often overlooked finding of the landmark study undertaken by Al-Hajj et al. [26] was that CD44+CD24+ breast cancer populations also remained viable and exhibited tumourigenicity in xenotransplantation studies but seemingly possessed reduced proliferative capacity compared to the CD44+CD24−/low cells that were taken to represent the stem-like fraction. The gene discussed is CD44; the disease is breast cancer.